Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key
molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular …

Cyclin dependent kinase 5 (CDK5) is a serine/threonine kinase belonging to the cyclin
dependent kinase (CDK) family. CDK5 is involved in numerous neuronal diseases …

Here is described a structural model for the binary complex CDK5–roscovitine. Roscovitine
has been shown to potently inhibit cyclin-dependent kinases 1, 2 and 5 (CDK1, 2, and 5) …

Casein kinase 1 delta (CK1δ) and its closest homologue CK1ε are key regulators of diverse
cellular growth and survival processes such as Wnt signaling, DNA repair, and circadian …

Cyclin‐dependent kinases (cdk) control the cell division cycle (cdc). These kinases and their
regulators are frequently deregulated in human tumours. A potent inhibitor of cdks …

The cyclin-dependent kinases (CDK) CDK1, CDK2, CDK4, and CDK6 are serine/threonine
protein kinases targeted in cancer therapy due to their role in cell cycle progression. The …

Abstract Cyclin-dependent kinase 5 (CDK5) is the serine/threonine-directed kinase mainly
found in the brain and plays a significant role in developing the central nervous system …

Pharmacological inhibitors of cyclin-dependent kinases (CDKs) have a wide therapeutic
potential. Among the CDK inhibitors currently under clinical trials, the 2, 6, 9-trisubstituted …

Aberrant control of cyclin-dependent kinases (CDKs) is a central feature of the molecular
pathology of cancer. Iterative structure-based design was used to optimize the ATP …

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …